Patient characteristics
| Patients . | Total . | Pre-HAART era . | HAART era . |
|---|---|---|---|
| HIV-1 patients with DLBCL | |||
| Patients, no. (%) | 41 | 12/41 (29.3) | 29/41 (70.7) |
| Median age, y (range) | 40 (22-62) | 37 (29-53) | 40 (22-62) |
| No. of men/no. of women (%) | 36/5 (87.8/12.2) | 12/0 | 24/5 (82.8/17.2) |
| Stage III/IV (%) | 21/41(51.2) | 7/12 (58.3) | 14/29 (48.3) |
| B symptoms (%) | 21/41 (51.2) | 11/12 (91.7) | 10/29 (34.5) |
| ≥1 extranodal site at presentation (%) | 26/41 (63.4) | 8/12 (66.7) | 18/29 (62.1) |
| aaIPI score 2-3 (%)* | 19/40 (47.5) | 9/12 (75) | 10/28 (35.7) |
| Bone marrow infiltration (%) | 7/41 (17.1) | 3/12 (25) | 4/29 (13.8) |
| Cerebrospinal fluid involvement (%) | 5/41 (12.2) | 3/12 (25) | 2/29 (6.9) |
| Known HIV infection prior to AR-DLBCL (%) | 34/41(82.9) | 11/12 (91.7) | 23/29 (79.3) |
| Median time between HIV and AR-DLBCL for known HIV patients, mo (range) | 37.3 (1.37-122.43) | 49.7 (4.53-83.2) | 37 (1.37-122.43) |
| AIDS diagnosis prior to AR-DLBCL, no. (%) | 18/41 (43.9) | 8/12 (66.7) | 10/29 (34.5) |
| Median CD4 count per mm3 (range) | 85.5 (10-840) | 25 (10-150) | 100 (12-840) |
| HIV index 2-4 (%)† | 29/40 (72.5) | 9/11 (81.8) | 20/29 (69) |
| DLBCL patients without HIV | |||
| Patients, no. | 53 | ||
| Median age, y (range) | 53 (19-86) | ||
| No. of men/no. of women (%) | 37/16 (69.8/30.2) | ||
| Stage III/IV (%) | 30/53 (56.6) | ||
| ≥1 extranodal site at presentation (%) | 14/53 (26.4) | ||
| IPI score 4-5 (%)‡ | 9/52 (17.3) | ||
| Bone marrow infiltration (%) | 7/53 (13.2) | ||
| Patients . | Total . | Pre-HAART era . | HAART era . |
|---|---|---|---|
| HIV-1 patients with DLBCL | |||
| Patients, no. (%) | 41 | 12/41 (29.3) | 29/41 (70.7) |
| Median age, y (range) | 40 (22-62) | 37 (29-53) | 40 (22-62) |
| No. of men/no. of women (%) | 36/5 (87.8/12.2) | 12/0 | 24/5 (82.8/17.2) |
| Stage III/IV (%) | 21/41(51.2) | 7/12 (58.3) | 14/29 (48.3) |
| B symptoms (%) | 21/41 (51.2) | 11/12 (91.7) | 10/29 (34.5) |
| ≥1 extranodal site at presentation (%) | 26/41 (63.4) | 8/12 (66.7) | 18/29 (62.1) |
| aaIPI score 2-3 (%)* | 19/40 (47.5) | 9/12 (75) | 10/28 (35.7) |
| Bone marrow infiltration (%) | 7/41 (17.1) | 3/12 (25) | 4/29 (13.8) |
| Cerebrospinal fluid involvement (%) | 5/41 (12.2) | 3/12 (25) | 2/29 (6.9) |
| Known HIV infection prior to AR-DLBCL (%) | 34/41(82.9) | 11/12 (91.7) | 23/29 (79.3) |
| Median time between HIV and AR-DLBCL for known HIV patients, mo (range) | 37.3 (1.37-122.43) | 49.7 (4.53-83.2) | 37 (1.37-122.43) |
| AIDS diagnosis prior to AR-DLBCL, no. (%) | 18/41 (43.9) | 8/12 (66.7) | 10/29 (34.5) |
| Median CD4 count per mm3 (range) | 85.5 (10-840) | 25 (10-150) | 100 (12-840) |
| HIV index 2-4 (%)† | 29/40 (72.5) | 9/11 (81.8) | 20/29 (69) |
| DLBCL patients without HIV | |||
| Patients, no. | 53 | ||
| Median age, y (range) | 53 (19-86) | ||
| No. of men/no. of women (%) | 37/16 (69.8/30.2) | ||
| Stage III/IV (%) | 30/53 (56.6) | ||
| ≥1 extranodal site at presentation (%) | 14/53 (26.4) | ||
| IPI score 4-5 (%)‡ | 9/52 (17.3) | ||
| Bone marrow infiltration (%) | 7/53 (13.2) | ||
aaIPI score includes 3 risk factors: Non-Hodgkin's Lymphoma (NHL) stage III/IV, performance status 2-4, and elevated serum lactic dehydrogenase.
HIV index encompasses 4 risk factors: age > 35 y, NHL stage III/IV, CD4 cell count < 100 per mm3, and injection drug use.
IPI score includes 5 risk factors: age > 60 y, NHL stage III/IV, performance status 2-4, elevated lactic dehydrogenase, and ≥2 extranodal sites.